Endocrine patterns in patients with benign and malignant prostatic diseases

Prostate

Volumn 44, Issue 3, 2000, Pages 219-224

  Schatzl, Georg ^a   Reiter, Werner J ^a   Thürridl, Thomas ^a   Waldmüller, Julia ^a   Roden, Michael ^a   Söregi, Stefan ^a   Madersbacher, Stephan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

BPH; Cortisol; Prostate cancer; Testosterone

Indexed keywords

ESTRADIOL; FOLLITROPIN; HYDROCORTISONE; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; STEROID HORMONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RADIOIMMUNOASSAY;

EID: 0034255832     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000801)44:3<219::AID-PROS6>3.0.CO;2-I     Document Type: Article

References (27)

1. Chan JM, Stampfer MJ, Giovannucci EL. What causes prostate cancer? A brief summary of the epidemiology. Semin Cancer Biol 1998;8:263-273.
2. Ekman P. Genetic and environmental factors in prostate cancer genesis: identifying high-risk cohorts. Eur Urol 1999;35:362-369.
3. Harper ME, Pierrepoint CG, Griffiths K. Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 1984;20:477-482.
4. Nomura A, Heilbrun LK, Stemmermann GN, Judd HL. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 1988;48:3515-3517.
5. Andersson SO, Adami HO, Bergström R, Wide L. Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer - a population-based case-control study. Br J Cancer 1993;68:97-102.
6. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev 1993;2:27-32.
7. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-1126.
8. Carter HB, Pearson JD, Metter EJ, Chan DW, Andres R, Fozard JL, Rosner W, Walsh PC. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995;27:25-31.
9. Mikkola AKK, Aro JLV, Rannikko SAS, Salo JO, on behalf of the FINNPROSTATE Group. Pretreatment plasma testosterone and etsradiol levels in patients with locally advanced or metastasized prostatic cancer. Prostate 1999;39:175-181.
10. Kroboth PD, Salek FS, Pittenger AL, Fabian TJ, Frye RF. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39:327-348.
11. Hechter O, Grossman A, Chatterton RT Jr. Relationship of dehydroepiandrosterone and cortisol in disease. Med Hypotheses 1997;49:85-91.
12. Lissoni P, Rovelli F, Giani L, Mandala M, Meregalli S, Barni S, Confalonieri G, Bonfanti A. Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasm: selective deficiency in metastatic disease. Int J Biol Markers 1998; 13:154-157.
13. van der Pompe G, Antoni MH, Heijnen CJ. Elevated basal cortisol levels and attenuated ACTH and cortisol responses to a behavioral challenge in women with metastatic breast cancer. Psychoendocrinology 1996;21:361-374.
14. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999;80:930-934.
15. Comstock GW, Gordon GB, Hsing AW. The relationship of serum dehydroepiandrosterone and its sulfate to subsequent cancer of the prostate. Cancer Epidemiol Biomarkers Prev 1993;2: 219-221.
16. Stahl F, Schnorr D, Pilz C, Dörner G. Dehydroepiandrosterone (DHEA) levels in patients with prostatic cancer, heart diseases and under surgery stress. Exp Clin Endocrinol 1992;99:68-70.
17. Brolin J, Skoog L, Ekman P. Immunohistochemistry and biochemistry in detection of androgen, progesterone, and estrogen receptors in benign and malignant human prostatic tissue. Prostate 1992;20:281-295.
18. Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D'Amato E, Casto ML, Vidali G, Castagnetta L. Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res 1994;54:1190-1193.
19. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarker Prev 1997;6:557-563.
20. Daniell HW. A better prognosis for obese men with prostate cancer. J Urol 1996;155:220-225.
21. Hammond GL. Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins. Endocr Rev 1990; 11:65-79.
22. Misao R, Iwagaki S, Sun WS, Fujimoto J, Tamaya T. Levels of corticosteroid-binding globulin mRNA in human ovarian cancers. Tumour Biol 1999;20:263-269.
23. Carlstrom K, Stege R. Testicular and adrenocortical function in men with prostatic cancer and in healthy age-matched controls. Br J Urol 1997;79:427-431.
24. Heikkila R, Aho K, Heliovaara M, Hakama M, Marniemi J, Reunanen A, Knekt P. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999;86:312-315.
25. Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, Berger P. Novel Coexpression of gonadotropic hormones and their corresponding LH/CG-receptors in the human prostate. Prostate 1998;35:212-220.
26. Reiter E, Hennuy B, Bruyninx M, Cornet A, Klug M, McNamara M, Closset J, Hennen G. Effects of pituitary hormones on the prostate. Prostate 1999;38:159-165.
27. Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, Szalay A, Djavan B, Schmidbauer CP, Söregi S, Madersbacher S, for the Prostate Study Group of the Austrian Society of Urology. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status and LUTS function. Urology 2000;55:397-402.